



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/773,480	02/06/2004	Michel Dib	FRAV2003/0003 US NP	7069
5487	7590	10/27/2008	EXAMINER	
ANDREA Q. RYAN			KIM, JENNIFER M	
SANOFI-AVENTIS U.S. LLC			ART UNIT	PAPER NUMBER
1041 ROUTE 202-206				1617
MAIL CODE: D303A				
BRIDGEWATER, NJ 08807				
NOTIFICATION DATE		DELIVERY MODE		
10/27/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com  
andrea.ryan@sanofi-aventis.com

<b>Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/773,480	DIB ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	JENNIFER M. KIM	1617	

All participants (applicant, applicant's representative, PTO personnel):

(1) JENNIFER M. KIM. (3) \_\_\_\_\_.

(2) Mr. Bell. (4) \_\_\_\_\_.

Date of Interview: 20 October 2008.

Type: a) Telephonic b) Video Conference  
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: Pending Claims.

Identification of prior art discussed: none.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Bell discussed that the compound of the instant invention have a better affinity to both the 5HT1a and the 5HT2c receptors and a low affinity for the M2 and M3 receptors compared with cveremazine, which was not only unexpected but also highly unpredictable.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

**THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW.** (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/JENNIFER M KIM/  
Primary Examiner, Art Unit 1617